Atossa Therapeutics (ATOS) Accounts Payables (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Accounts Payables of $2.6 million for Q1 2026, up 120.52% year-over-year from $1.2 million in Q1 2025, and down 40.16% quarter-over-quarter from $4.3 million in Q4 2025.
Atossa Therapeutics (ATOS) Accounts Payables (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Accounts Payables for 16 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 120.52% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (up 120.52% YoY), while the FY2025 annual figure was $4.3 million, up 532.25% from the prior year.
- Accounts Payables eased to $2.6 million in Q1 2026 per ATOS's latest filing, from $4.3 million in the prior quarter.
- Across five years, Accounts Payables topped out at $4.3 million in Q4 2025 and bottomed at $679000.0 in Q4 2024.
- Historically, Accounts Payables has averaged $1.8 million across 5 years, with a median of $1.6 million in 2024.
- Annual changes were most pronounced in 2023 — Accounts Payables plunged 72.82% — and 2025, when it surged 532.25%.
- Atossa Therapeutics' Accounts Payables stood at $3.0 million in 2022, then tumbled by 72.82% to $806000.0 in 2023, then declined by 15.76% to $679000.0 in 2024, then soared by 532.25% to $4.3 million in 2025, then tumbled by 40.16% to $2.6 million in 2026.
- Business Quant data shows ATOS's Accounts Payables at $2.6 million in Q1 2026, $4.3 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | 1.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.98 Mn |
| Mar 31, 2026 | 2.57 Mn |
| Dec 31, 2025 | 4.29 Mn |
| Sep 30, 2025 | 3.54 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 679,000.00 |
| Sep 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | 1.06 Mn |
| Mar 31, 2024 | 1.23 Mn |
| Dec 31, 2023 | 806,000.00 |
| Sep 30, 2023 | 718,000.00 |
| Jun 30, 2023 | 1.17 Mn |
| Mar 31, 2023 | 1.44 Mn |
| Dec 31, 2022 | 2.97 Mn |
| Sep 30, 2022 | 1.65 Mn |
| Jun 30, 2022 | 2.05 Mn |
| Mar 31, 2022 | 1.60 Mn |
| Dec 31, 2021 | 1.72 Mn |
| Sep 30, 2021 | 667,988.00 |